Media coverage
5
Media coverage
Title Inspirna Announces Interim Data from Phase 1b/2 Study of Abequolixron (RGX-104) in Relapsed or Refractory Lung Cancer Media name/outlet Business Wire Country/Territory United States Date 01/5/23 URL www.businesswire.com/news/home/20230105005235/en/Inspirna-Announces-Interim-Data-from-Phase-1b2-Study-of-Abequolixron-RGX-104-in-Relapsed-or-Refractory-Lung-Cancer/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT Persons Hossein Borghaei Title Inspirna Announces Interim Data from Phase 1b/2 Study of Abequolixron (RGX-104) in Relapsed or Refractory Lung Cancer; Abequolixron in combination with docetaxel in heavily-pretreated NSCLC and SCLC is well tolerated and demonstrates encouraging prelimina Media name/outlet Business Wire Country/Territory United States Date 01/5/23 Persons Hossein Borghaei Title Inspirna Announces Interim Data from Phase 1b/2 Study of Abequolixron (RGX-104) in Relapsed or Refractory Lung Cancer Media name/outlet BioSpace Country/Territory United States Date 01/5/23 URL https://www.biospace.com/article/releases/inspirna-announces-interim-data-from-phase-1b-2-study-of-abequolixron-rgx-104-in-relapsed-or-refractory-lung-cancer/ Persons Hossein Borghaei Title Inspirna Announces Interim Data from Phase 1b/2 Study of Abequolixron (RGX-104) in Relapsed or Refractory Lung Cancer Media name/outlet Yahoo! Finance Country/Territory United States Date 01/5/23 URL https://finance.yahoo.com/news/inspirna-announces-interim-data-phase-130000261.html Persons Hossein Borghaei Title Inspirna Announces Interim Data from Phase 1b/2 Study of Abequolixron (RGX-104) in Relapsed or Refractory Lung Cancer Media name/outlet Le Lezard.com Country/Territory Canada Date 01/5/23 URL https://www.lelezard.com/en/news-20722611.html Persons Hossein Borghaei